Patents Issued in March 22, 2018
  • Publication number: 20180078597
    Abstract: The present invention is based on the surprising antiseptic nature of chlorhexidine when combined with essential oils. It has been found that chlorhexidine, combined with an essential oil, is surprisingly effective at penetrating the skin surface and providing an antiseptic effect within the skin. It has also been found that a combination of chlorhexidine and eucalyptus oil is surprisingly effective as an antimicrobial against Staphylococcus epidermidis.
    Type: Application
    Filed: November 28, 2017
    Publication date: March 22, 2018
    Inventors: TONY WORTHINGTON, TARJA KARPANEN
  • Publication number: 20180078598
    Abstract: Compositions and processes are disclosed for a capsule, tablet, or pill comprised of powdered strawberries. Fresh strawberries are washed, de-calyxed, and then processed into a dry pulp. The dry pulp may be pulverized to a desired granularity. In some embodiments, the pulp may be filtered to remove the seeds, prior to drying. In some embodiments the fruit may be dried by way of freeze drying, hot air drying, or spray-dried. Additional vitamins and minerals may be included with the powdered strawberries to impart further health benefits to the composition. An advantage of this composition is that it serves several functions, including providing a good source of antioxidants, phytochemicals, and flavonoids. As such, the composition may be useful for mitigating various types of cancer, heart disease, high cholesterol, high blood pressure, cataracts, arthritis, skin damage from UV rays, anti-aging, and the like.
    Type: Application
    Filed: September 20, 2017
    Publication date: March 22, 2018
    Inventor: Dan Legard
  • Publication number: 20180078599
    Abstract: This document provides methods and materials for treating cancer. For example, this document provides methods for using compositions containing a potato polysaccharide preparation to reduce the number of cancer cells in a mammal. In some cases, a composition containing a potato polysaccharide preparation provided herein can be used to reduce the number of cancer cells in a mammal, wherein the cancer cells express a KRAS polypeptide.
    Type: Application
    Filed: March 25, 2016
    Publication date: March 22, 2018
    Inventors: George B. Stefano, Richard M. Kream, Kirk J. Mantione
  • Publication number: 20180078600
    Abstract: Diverse antioxidant supplements boost humans' ability to combat exposure to ultraviolet radiation (without being a substitute for sunscreen) and may be delivered effectively with many vehicles, enhancing user compliance.
    Type: Application
    Filed: September 16, 2017
    Publication date: March 22, 2018
    Inventor: Eric Lund
  • Publication number: 20180078601
    Abstract: An oral formulation includes a plurality of agents that promote cellular detoxification. Agents can be included that modulate expression of Nrf2-associated genes upon ingestion of the oral formulation by a subject, wherein the Nrf2-associated genes include at least one gene encoding intrinsic antioxidants, and at least one gene encoding cellular detoxifiers. In addition, at least one of the plurality of agents attenuates inflammation.
    Type: Application
    Filed: August 13, 2017
    Publication date: March 22, 2018
    Applicant: NSE Products, Inc.
    Inventors: Angela Mastaloudis, Steve Wood, Jamie Louis Barger, Richard Weindruch, Tomas Alberto Prolla, Mark Bartlett, Scott B. Ferguson
  • Publication number: 20180078602
    Abstract: The duration of treatment of erectile dysfunction (“ED”) with phosphodiesterase inhibitors can be extended by concomitant administrations of compositions comprising ginger, and a compound that produces L-arginine in vivo. Preferred compositions of the present invention comprise ginger, L-citrulline, Muira Puama and Paullinia cupana. The compositions are administered in a pharmaceutically effective amount for a sufficient period of time to treat or as a prophylaxis against ED or conditions associated with tissue fibrosis.
    Type: Application
    Filed: March 4, 2016
    Publication date: March 22, 2018
    Inventors: Mauro Milchteim, Floyd Alexander Katske, Jacob Rajfer
  • Publication number: 20180078603
    Abstract: The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.
    Type: Application
    Filed: September 21, 2017
    Publication date: March 22, 2018
    Inventors: Allen RADIN, Neil GRAHAM, Bolanle AKINLADE, Gianluca PIROZZI, Xing SUN, Thomas HULTSCH, Brad S. SHUMEL, Ashish BANSAL
  • Publication number: 20180078604
    Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
    Type: Application
    Filed: November 7, 2017
    Publication date: March 22, 2018
    Inventors: Gerold L. MOSHER, David W. MILES
  • Publication number: 20180078605
    Abstract: The invention provides a method of prevention, inhibition or treatment of uremic pruritus in a dialysis patient by administering an effective amount of a kappa opioid receptor agonist. Also provided is a method of inhibition or treatment of adverse symptoms associated with dialysis affecting the quality of life of dialysis patient, the method includes administering an effective amount of a kappa opioid receptor agonist. The adverse symptoms associated with dialysis addressable by the methods of the invention include uremic pruritus, sleep disruption, depression and other mood alterations.
    Type: Application
    Filed: November 13, 2017
    Publication date: March 22, 2018
    Applicant: Cara Therapeutics, Inc.
    Inventors: Robert H. SPENCER, Frédérique MENZAGHI, Derek T. CHALMERS
  • Publication number: 20180078606
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: May 3, 2017
    Publication date: March 22, 2018
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20180078607
    Abstract: This invention relates to ?A-crystallin protein modulating compounds (e.g., phosphomimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment and prevention of conditions involving neurodegeneration and neuroinflammation.
    Type: Application
    Filed: September 18, 2017
    Publication date: March 22, 2018
    Inventors: Patrice E. Fort, Kevin Schey
  • Publication number: 20180078608
    Abstract: The present invention is related to methods and compositions useful in the detection and treatment of epigenetic changes during traumatic, autoimmune and other disease processes. The methods described herein comprise identifying and using certain agents to modulate pathophysiological processes in animal and human subjects. The methods of the invention may be used for therapeutic or diagnostic purposes.
    Type: Application
    Filed: September 16, 2016
    Publication date: March 22, 2018
    Inventor: Desmond D. Mascarenhas
  • Publication number: 20180078609
    Abstract: The invention, in part, relates to the use of optogenetic methods to increase dendritic spine density on DG memory engram cells in treatment methods for memory-impairment-associated diseases and conditions.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 22, 2018
    Applicant: Massachusetts Institute of Technology
    Inventors: Susumu Tonegawa, Dheeraj Roy
  • Publication number: 20180078610
    Abstract: The present invention relates to hot flash-suppressing agents and menopause-improving agents and a food and drink and a pharmaceutical preparation for suppressing hot flash, containing ?-lactalbumin as an active ingredient.
    Type: Application
    Filed: April 6, 2016
    Publication date: March 22, 2018
    Applicant: MEIJI CO., LTD.
    Inventors: Masayuki UCHIDA, Orie KOBAYASHI
  • Publication number: 20180078611
    Abstract: This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines.
    Type: Application
    Filed: September 14, 2017
    Publication date: March 22, 2018
    Inventors: Eckhard R. Podack, Vadim Deyev, Robert Levy
  • Publication number: 20180078612
    Abstract: This disclosure describes, in one aspect, a composition for intracellular delivery of a polypeptide. Generally, the composition includes a substrate that has a surface, a cleavable linker affixed to at least a portion of the surface, and a cargo polypeptide bound to the cleavable linker. In some embodiments, the cargo polypeptide can further include a targeting peptide. In another aspect, this disclosure describes a method for intracellular delivery of a polypeptide. Generally, the method includes administering to a subject any embodiments of the composition summarized above, and cleaving the cleavable linker, thereby releasing the cargo polypeptide from the substrate.
    Type: Application
    Filed: December 4, 2017
    Publication date: March 22, 2018
    Inventors: Joseph A. Zasadzinski, Norbert O. Reich, Gary B. Braun, Demosthenes P. Morales, Xiao Huang
  • Publication number: 20180078613
    Abstract: Provided are pharmaceutical compositions including macrophage activating factor derived from Gc protein (GcMAF) for use in treating benign or precancerous papillomas. Further provided are pharmaceutical compositions including GcMAF for use in treating recurrent respiratory papillomatosis (RRP).
    Type: Application
    Filed: April 6, 2016
    Publication date: March 22, 2018
    Applicant: EFRANAT LTD.
    Inventors: Michal SHAHAR, Uri YOGEV, Rinat ROTEM-YEHUDAR
  • Publication number: 20180078614
    Abstract: Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 22, 2018
    Applicant: REPONEX PHARMACEUTICALS APS
    Inventor: Lars Heslet
  • Publication number: 20180078615
    Abstract: The present invention concerns compositions and methods for inhibition of abnormal uterine bleeding (AUB), such as that associated with use of long-acting progestin-only contraceptives (LAPCs). An aspect of the invention concerns compositions comprising chemokine (C-C motif) ligand 2 (CCL2), or a biologically active fragment thereof, which may administered to subjects for inhibition of AUB. Another aspect of the invention concerns methods for inhibiting AUB, comprising administering an effective amount of CCL2, or a biologically active fragment thereof, to a subject in need thereof. Another aspect of the invention concerns a kit for inhibiting AUB.
    Type: Application
    Filed: March 23, 2016
    Publication date: March 22, 2018
    Inventors: CHARLES JOSEPH LOCKWOOD, UMIT ALI KAYISLI, MURAT BASAR, OZLEM GUZELOGLU-KAYISLI, NIHAN SEMERCI, FREDERICK SCHATZ
  • Publication number: 20180078616
    Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier, and administering a therapeutic agent. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
    Type: Application
    Filed: August 14, 2017
    Publication date: March 22, 2018
    Inventor: Henry HSU
  • Publication number: 20180078617
    Abstract: The invention provides compounds such as proteins, peptides, peptidomimetics and small molecules, methods for treating cell proliferative disorders such as neoplasia, tumor, or cancer, and metastasis thereof, and methods for identifying and screening for active compounds.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 22, 2018
    Applicant: KALOS Therapeutics
    Inventor: MICHAEL KOZLOWSKI
  • Publication number: 20180078618
    Abstract: Compositions and methods for treating endothelial glycocalyx include glucosamine, hyaluronan and/or fucoidan, and one or more antioxidants, such as superoxide dismutase, catalase, and/or polyphenol. The compositions improve vascular health by exhibiting beneficial synergistic effects on endothelial glycocalyx over the benefits of taking any single component alone or the sum of reported effects of the individual components. Specifically, components of the composition (1) enhance synthesis of new glycocalyx by (a) providing and (b) increasing production of glycocalyx precursors, (2) protecting existing glycocalyx against damage, such as by oxidation degradation, by (a) providing and (b) increasing production of antioxidants, some of which associate with endothelial glycocalyx, and (3) enhance repair of damaged glycocalyx by (a) providing glycocalyx mimetics and (b) increasing the prevalence of glycocalyx scaffold for association and incorporation thereof.
    Type: Application
    Filed: November 28, 2017
    Publication date: March 22, 2018
    Inventors: Robert Maxfield Long, Hans Vink
  • Publication number: 20180078619
    Abstract: Provided is an antibacterial composition against carbapenem-resistant gram-negative bacteria which includes, as an active ingredient, adenylate kinase (ADK) protein derived from Mycobacterium tuberculosis. The ADK protein derived from Mycobacterium tuberculosis, according to the subject matter, has excellent antimicrobial activity against carbapenem-resistant gram-negative bacteria, and thus may be usefully used in a variety of fields as an antibacterial composition.
    Type: Application
    Filed: April 4, 2016
    Publication date: March 22, 2018
    Applicant: KONKUK UNIVERSITY GLOCAL INDUSTRY-ACADEMIC COLLABORATION FOUNDATION
    Inventors: Yeong Min PARK, In Duk JUNG, Seung Jun LEE
  • Publication number: 20180078620
    Abstract: Provided are a method of preventing and/or treating an eye disease, using a Cas9 protein and a guide RNA targeting VEGF-A, and a ribonucleoprotein including a Cas9 protein and a guide RNA targeting VEGF-A.
    Type: Application
    Filed: July 27, 2017
    Publication date: March 22, 2018
    Inventors: Jin-Soo KIM, Jeong Hun KIM, Sung Wook PARK, Kyoungmi KIM
  • Publication number: 20180078621
    Abstract: Disclosed are a hypotonic composition for fat decomposition and a method for preparing the same. That is, according to the present invention, a hypotonic composition for fat decomposition is prepared to contain sodium deoxycholate, hyaluronidase, and the like in a hypotonic solution composed of distilled water and sodium hydrochloride.
    Type: Application
    Filed: September 21, 2017
    Publication date: March 22, 2018
    Inventors: KYOUNG LACK LEE, SI HA KANG
  • Publication number: 20180078622
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 22, 2018
    Inventor: Andrew M. Blumenfeld
  • Publication number: 20180078623
    Abstract: A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed.
    Type: Application
    Filed: May 11, 2017
    Publication date: March 22, 2018
    Inventor: Joan M. Fallon
  • Publication number: 20180078624
    Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.
    Type: Application
    Filed: March 11, 2016
    Publication date: March 22, 2018
    Applicant: SYZ CELL THERAPY CO.
    Inventors: Xiangjun ZHOU, Jin LI, Yanyan HAN, Dongyun WU, Junyun LIU, Ran TAO, Longqing TANG
  • Publication number: 20180078625
    Abstract: The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).
    Type: Application
    Filed: March 25, 2016
    Publication date: March 22, 2018
    Inventors: James J. Moon, Rui Kuai, Anna A. Schwendeman, Jutaek Nam
  • Publication number: 20180078626
    Abstract: The present invention provides compositions and methods for treating renal cell carcinoma
    Type: Application
    Filed: March 30, 2016
    Publication date: March 22, 2018
    Inventors: David AVIGAN, Jacalyn ROSENBLATT, Donald KUFE
  • Publication number: 20180078627
    Abstract: There is provided a method of loading antigen in a dendritic cell for antigen presentation, the method comprising: modifying a pluripotent stem cell with a nucleic acid molecule encoding an antigen or one or more immunogenic epitopes thereof; inducing the pluripotent stem cell to differentiate into a dendritic cell that expresses and presents the antigen or the one or more immunogenic epitopes thereof. Dendritic cells, vaccines and methods of using the dendritic cells and vaccines are also provided.
    Type: Application
    Filed: March 28, 2016
    Publication date: March 22, 2018
    Inventors: Jieming ZENG, Shu WANG, Andrew KHOO
  • Publication number: 20180078628
    Abstract: A method is disclosed for treating small cell lung cancer (SCLC) in a subject that involves administering to the subject a therapeutically effective amount of dendritic cells engineered to overexpress p53. In some embodiments, the method further involves administering to the subject a therapeutically effective amount of all-trans-retinoic acid (ATRA). The method can also involve administering to the subject a therapeutically effective amount of an immune checkpoint inhibitor.
    Type: Application
    Filed: April 4, 2016
    Publication date: March 22, 2018
    Inventors: Scott Antonia, Alberto Chiappori
  • Publication number: 20180078629
    Abstract: The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (MHC) class I restricted antigen presentation. The present invention furthermore relates to a method of vaccination of a mammal using the inventive vaccine/inhibitor combination. The present invention also provides kit of parts comprising the inventive vaccine/inhibitor combination, preferably in different parts of the kit, e.g. for prior, concurrent or subsequent administration of the different parts. Additionally the invention relates to a pharmaceutical composition comprising the inventive vaccine/inhibitor combination to further improve the immune response against tumour cells and infected cells having lost the capability of MHC class I restricted antigen presentation.
    Type: Application
    Filed: July 21, 2017
    Publication date: March 22, 2018
    Applicant: CureVac AG
    Inventors: Christina LORENZ, Mariola FOTIN-MLECZEK, Karl-Josef KALLEN
  • Publication number: 20180078630
    Abstract: The present invention relates to synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 that are related to carbapenem-resistant Klebsiella pneumoniae capsular polysaccharide and conjugates thereof. Said conjugates and pharmaceutical composition containing said conjugates are useful for prevention and/or treatment of diseases associated with carbapenem-resistant Klebsiella pneumoniae. Furthermore, the synthetic saccharides of general formula (I): V*—[Ux+2—Ux+1—Ux]n—V—O-L-NH2 are useful as marker in immunological assays for detection of antibodies against carbapenem-resistant Klebsiella pneumoniae bacteria.
    Type: Application
    Filed: March 29, 2016
    Publication date: March 22, 2018
    Inventors: Peter H. Seeberger, Claney Lebev Pereira, Guozhi Xiao, Naeem Khan, Chakkumkal Anish
  • Publication number: 20180078631
    Abstract: Compositions comprising a nucleic acid molecule that encodes TB esat-6 proteins are disclosed. Methods of inducing an immune response against TB an individual are disclosed. Method of treating an individual who has been diagnosed with TB are disclosed. Method of preventing TB infection in an individual are disclosed.
    Type: Application
    Filed: September 26, 2017
    Publication date: March 22, 2018
    Inventors: David B. Weiner, Daniel Villarreal
  • Publication number: 20180078632
    Abstract: The invention relates to a novel VHH construct which can be bounded by a complete antibody without impairment of the antigen binding properties of the VHH construct being impaired. The invention also relates to an antibody construct comprising a VHH construct of this type and a kit, as well as the use thereof in immunodiagnostics or in the area of therapeutics. With the invention, among other things, it is possible to direct the existing immunity of a patient toward a different antigen.
    Type: Application
    Filed: April 11, 2016
    Publication date: March 22, 2018
    Inventors: Jonas FUENER, Angelo BOLCHI, Erik SCHLIEBS, Simone OTTONELLO
  • Publication number: 20180078633
    Abstract: Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 22, 2018
    Applicant: St. Jude Children's Research Hospital
    Inventors: Elaine Tuomanen, Elizabeth R. Mann
  • Publication number: 20180078634
    Abstract: The present invention relates to prophylactic and/or therapeutic vaccines that contain Newcastle disease virus (NDV) virus-like particles (VLPs) comprising one or more Epstein-Barr Virus (EBV) antigens. In one embodiment, the invention provides a recombinant virus-like particle (VLP) comprising, in operable combination, a) Newcastle disease virus (NDV) matrix (M) protein, and b) one or more Epstein-Barr Virus (EBV) antigens. The invention's prophylactic and/or therapeutic vaccines are useful for preventing and/or treating infection with EBV and/or disease associated Epstein-Barr Virus, such as cancer.
    Type: Application
    Filed: March 16, 2016
    Publication date: March 22, 2018
    Applicant: THE UNIVERSITY OF MASSACHUSETTS
    Inventors: Javier Gordon Ogembo, Trudy Morrison
  • Publication number: 20180078635
    Abstract: The present invention provides a vaccine formulation, a preparation method therefor and a use thereof. The vaccine formulation comprises a vaccine carrier and an antigen component, wherein the vaccine carrier is obtained by hydrothermal transformation of microorganisms. The vaccine formulation of the present invention is obtained by compounding the vaccine carrier obtained by hydrothermal transformation of microorganisms with the antigen component.
    Type: Application
    Filed: November 18, 2015
    Publication date: March 22, 2018
    Inventors: Guanghui MA, Wei WEI, Dezhi NI, Hua YUE, Weiqing ZHOU, Piping LV
  • Publication number: 20180078636
    Abstract: A fusion protein for use as a hepatitis B therapeutic vaccine is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant that lacks amino acids (aa) at least from as 21 to as 50. The protein transduction domain is a fusion polypeptide comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein transduction domain.
    Type: Application
    Filed: September 11, 2017
    Publication date: March 22, 2018
    Inventors: Chia-Mao WU, Jiun-Ming Wu, Yi-Chia Lin, Kung-Lung Lee, Chia-Hao Kang, Fu-Hsien Chiang, Cheng-Yung Chang, Wei-Lun Chang, Hsiang-Kai Lin, Chia-Kuan Peng, Wei-Hsiang Lin, Yi-Tsui Chiu
  • Publication number: 20180078637
    Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.
    Type: Application
    Filed: August 23, 2017
    Publication date: March 22, 2018
    Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Alessandro Sette, Carla Oseroff, Howard Grey, Bjoern Peters
  • Publication number: 20180078638
    Abstract: Disclosed herein is a vaccine comprising an antigen and ISG15. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating a subject in need thereof. The methods may comprise administering the vaccine to the subject.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 22, 2018
    Inventors: David Weiner, Daniel Villarreal
  • Publication number: 20180078639
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 22, 2018
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • Publication number: 20180078640
    Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 22, 2018
    Inventors: Bo Yu, Rijian WANG, Keith REIMANN
  • Publication number: 20180078641
    Abstract: The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation. More specifically, the method involves removing a bodily fluid from a patient, attaching an antibody to pathogens in the bodily fluid, sensing the antibody-pathogen moiety, using a high-powered, focused laser, or other suitable light source, to destroy the antibody-pathogen moiety, removing the remains of the antibody-pathogen by filtering or other suitable mechanism(s), and returning the bodily fluid to the patient.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 22, 2018
    Inventors: Mitchell S. Felder, Danny W. Muse
  • Publication number: 20180078642
    Abstract: Edible compositions are provided and comprise a soluble mineral component and/or a phosphate component in amounts effective for use as an oral medicament. The soluble mineral component comprises one or more minerals selected from the group consisting of zinc, manganese, tin, copper, and mixtures thereof. The edible compositions are advantageously companion animal chews, treats or supplements. Further disclosed are methods of making the chews, treats or supplements as are methods of treating conditions of the oral cavity.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 22, 2018
    Applicant: Mars, Incorporated
    Inventors: Edward Russell Cox, Douglas Joseph Dobrozsi, Thomas Edward Huetter, Allan John Lepine, Susan Ruth Ward
  • Publication number: 20180078643
    Abstract: Topical compositions comprising a corticosteroid, at least one alcohol, and a penetration enhancing agent.
    Type: Application
    Filed: November 22, 2017
    Publication date: March 22, 2018
    Inventors: Sateesh KANDAVILLI, Madhusudhan BOMMAGANI, Vijendra NALAMOTHU, Franklin OKUMU
  • Publication number: 20180078644
    Abstract: The invention describes the preparation and use of carotenoid and epi-lutein compositions to treat various ocular diseases.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 22, 2018
    Inventor: Thomas EIDENBERGER
  • Publication number: 20180078645
    Abstract: According to the invention there is provided inter alia an aqueous liquid pharmaceutical formulation comprising insulin or an insulin analogue, ionic zinc, a chelating agent and polysorbate 80.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 22, 2018
    Applicant: Arecor Limited
    Inventors: David GERRING, Leon Zakrzewski, Jan Jezek, Sarah Howell
  • Publication number: 20180078646
    Abstract: Disclosed is a tigecycline composition for injection, comprising the active component, tigecycline, and a propping agent. Also included is a stabilization agent. Also disclosed is a stable, pharmaceutically acceptable reconstitution liquid having freeze-dried tigecycline. The tigecycline composition for injection of the present invention has good redissolution, and can dissolve without intense shaking, thereby avoiding foams caused by intense shaking. Upon testing, the tigecycline composition and the tigecycline composition-diluted reconstitution liquid prepared in the present invention prove to have substantially lowered oxidation degradation and epimer generation and increased stability of the tigecycline preparation.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 22, 2018
    Applicant: Galenicum Health S.L.
    Inventor: Jihong Qin